Insmed Inc (INSM): Cost of Revenue
$122.94M
Year ended 2025-12-31
$188.22M
Trailing 12 months to 2026-06-30
+30.7%
3-year compound annual growth
+25.3%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $122.94M | +43.4% | 2026-02-19, From 2025-01-01 |
| 2024-12-31 | $85.74M | +30.8% | 2026-02-19, From 2024-01-01 |
| 2023-12-31 | $65.57M | +19.0% | 2026-02-19, From 2023-01-01 |
| 2022-12-31 | $55.13M | +24.9% | 2025-02-20, From 2022-01-01 |
| 2021-12-31 | $44.15M | +10.7% | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $39.87M | +64.7% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $24.21M | +899.3% | 2022-02-17, From 2019-01-01 |
| 2018-12-31 | $2.42M | n/a | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $0 | n/a | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | $0 | n/a | 2019-02-22, From 2016-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Insmed Inc (INSM) | 2025-12-31 | $122.94M | +43.4% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $400.94M | -18.9% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $100.71M | +161.7% |
| Organogenesis Holdings Inc. (ORGO) | 2024-12-31 | $115.74M | +8.7% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $336.35M | -3.6% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $77.67M | +27.5% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $74.56M | -4.3% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $363.83M | +1.6% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $149.75M | -12.1% |
Compare INSM, OPK, TGTX, ORGO side by side · Screen every company in Pharmaceutical Preparations ↗